Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke

The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.

Study Overview

• Status: Terminated
• Conditions: Ischemic Stroke
• Intervention / Treatment: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo

Detailed Description

The interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern.

• Study Type: Interventional
• Enrollment (Actual): 181
• Phase: Phase 2

Contacts and Locations

Study Locations

• Bulgaria
  • Pleven, Bulgaria, 5800
    • Voennomeditsinska Akademia - MBAL- Pleven, Otdelenie po Nervni bolesti
  • Plovdiv, Bulgaria, 4002
    • MBAL Kaspela
  • Sofia, Bulgaria, 1113
    • MBALNP "Sveti Naum" EAD, Klinika za Intenzivno Lechenie na Nervni Bolesti
  • Sofia, Bulgaria, 1202
    • Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie, Otdelenie po Nevrologia
  • Sofia, Bulgaria, 1407
    • MBAL "Tokuda Bolnitsa", Otdelenie po nevrologiya
  • Sofia, Bulgaria, 1431
    • Universitetska mnogoprofilna bolnitsa za aktivno lechenie Aleksandrovska, Klinika po Nevrologia
  • Sofia, Bulgaria, 1527
    • UMBAL Tsaritsa Yoanna, Klinika po nevrologia
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6L 5X8
      • Grey Nuns Community Hospital
• Czech Republic
  • Brno, Czech Republic, 65691
    • Fakultni nemocnice u sv. Anny v Brne
  • Plzen - Lochotin, Czech Republic, 304 60
    • Fakultni Nemocnice Plzen
• France
  • Bordeaux, France, 33076
    • CHU Pellegrin
  • Paris Cedex 13, France, 75651
    • Chu La Pitie Salpetriere
• Germany
  • Altenburg, Germany, 04600
    • Klinikum Altenburger Land
  • Essen, Germany, 45122
    • Universitaetsklinikum Essen, Neurologische Klinik
  • Leipzig, Germany, 04103
    • Universitaetsklinikum Leipzig
  • Muenchen, Germany, 81675
    • Klinikum Rechts der Isar, Neurologische Klinik
  • Muenster, Germany, 48149
    • Universitaetsklinikum Muenster
  • Regensburg, Germany, 93053
    • Universitaet Regensburg
• Hungary
  • Balassagyarmat, Hungary, 2660
    • Dr. Kennessey Albert Korhaz-Rendelointezet, Neurologiai Osztaly
  • Budapest, Hungary, 1076
    • Fovarosi Onkormanyzat Peterfy Sandor utcai Korhaz-Rendelointezet es Baleseti Kozpont/Neurologia
  • Budapest, Hungary, 1083
    • Semmelweis Egyetem AOK / Neurologiai Klinika
  • Budapest, Hungary, 1134
    • Honvedkorhaz-Allami Egeszsegugyi Kozpont, Ideggyogyaszati Osztaly
  • Budapest, Hungary, 1145
    • Orszagos Idegtudomanyi Intezet, Stroke-ambulancia
  • Gyor, Hungary, 9024
    • Petz Aladar Megyei Oktato Korhaz, Neurologiai Osztaly
• India
  • New Delhi, India, 110017
    • Max Super Speciality Hospital
  • Maharashtra
    • Pune, Maharashtra, India, 411011
      • KEM Hospital
• Korea, Republic of
  • Gwangju, Korea, Republic of, 501-757
    • Chonnam National University Hospital, Department of Neurology
  • Incheon, Korea, Republic of, 400-711
    • Inha University Hospital, Department of Neurology
  • Seoul, Korea, Republic of, 110-744
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 120-752
    • Severance Hospital, Yonsei University College of Medicine, Department of Neurology
  • Seoul, Korea, Republic of, 135710
    • Samsung Medical Center, Department of Neurology
  • Seoul, Korea, Republic of, 138-736
    • Asan Medical Center, Department of Neurology
  • Gyeonggi-do
    • Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
      • Seoul National University Bundang Hospital, Department of Neurology
  • Gyonggi-do
    • Anyang-si, Gyonggi-do, Korea, Republic of, 431-070
      • Hallym University Sacred Heart Hospital, Department of Neurology
• Taiwan
  • Kaohsiung, Taiwan, 833
    • Chang Gung Medical Foundation-Kaohsiung Chang Gung Memorial Hospital
  • Taichung, Taiwan, 404
    • China Medical University Hospital
  • Taipei, Taiwan, 100
    • National Taiwan University Hospital
  • Taoyuan County, Taiwan, 333
    • Chang Gung Medical Foundation-Linkou Branch
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • The Kirklin Clinic
    • Birmingham, Alabama, United States, 35233
      • Spain REhabilitation Center
    • Birmingham, Alabama, United States, 35294-3280
      • University Hospital
  • Florida
    • Deerfield Beach, Florida, United States, 33064
      • Broward Health North
    • Fort Lauderdale, Florida, United States, 33308
      • Neurologic Consultant, P.A.
    • Port Charlotte, Florida, United States, 33952
      • Neurostudies, Inc.
    • Port Charlotte, Florida, United States, 33952
      • Fawcett Memorial Hospital
  • Georgia
    • Columbus, Georgia, United States, 31909
      • Medical Research & Health Education Foundation, Inc.
    • Columbus, Georgia, United States, 31901
      • Jagdish Sidhpura M.D.
    • Columbus, Georgia, United States, 31904
      • Jose Canedo, M.D., West Georgia Neurology
    • Columbus, Georgia, United States, 31904
      • St. Francis Hospital
    • Columbus, Georgia, United States, 31907
      • Muscogee Manor & Rehabilitation Center
  • Indiana
    • Fort Wayne, Indiana, United States, 46805
      • Parkview Hospital Randallia
    • Fort Wayne, Indiana, United States, 46845
      • Parkview Regional Medical Center
    • Fort Wayne, Indiana, United States, 46845
      • Parkview Research Center
    • Fort Wayne, Indiana, United States, 46845
      • Fort Wayne Neurological Center
    • Huntington, Indiana, United States, 46750
      • Norwood Nursing Center
  • Massachusetts
    • Boston, Massachusetts, United States, 02129
      • Spaulding Rehabilitation Hospital
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital/Department of Neurology
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Wayne State University
  • Missouri
    • St. Louis, Missouri, United States, 63110
      • Barnes-Jewish Hospital
    • St. Louis, Missouri, United States, 63110
      • Rehabilitation Institute of St. Louis
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27514
      • UNC Healthcare
    • Chapel Hill, North Carolina, United States, 27599-7025
      • UNC Department of Neurology Stroke Division
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • OU Medical Center
    • Oklahoma City, Oklahoma, United States, 73104
      • Oklahoma University Health Sciences Center
    • Oklahoma City, Oklahoma, United States, 73104
      • Investigational Drug Services at OU Medical Center
    • Oklahoma City, Oklahoma, United States, 73104
      • OU Physicians Building
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Penn State Milton South Hershey Medical Center / Penn State College of Medicine
    • Hummelstown, Pennsylvania, United States, 17036
      • Penn State Hershey Rehabilitation Hospital
  • Texas
    • Houston, Texas, United States, 77030
      • The Methodist Hospital
    • Houston, Texas, United States, 77030
      • The Methodist Hospital Neurological Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 81 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.
• Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.
• Stroke involving upper extremity.
• Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.

Exclusion Criteria:

• Any other severe acute or chronic medical or psychiatric condition besides the stroke.
• Women of child bearing potential.
• Uncontrolled hypertension.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Other: Placebo; Placebo of PF-03049423 daily for 90 days
Experimental: 1 mg PF-03049423	Drug: PF-03049423; 1 mg of PF-03049423 daily for 90 days; Drug: PF-03049423; 3 mg of PF-03049423 daily for 90 days; Drug: PF-03049423; 6 mg of PF-03049423 daily for 90 days
Experimental: 3 mg of PF-03049423	Drug: PF-03049423; 1 mg of PF-03049423 daily for 90 days; Drug: PF-03049423; 3 mg of PF-03049423 daily for 90 days; Drug: PF-03049423; 6 mg of PF-03049423 daily for 90 days
Experimental: 6 mg of PF-03049423	Drug: PF-03049423; 1 mg of PF-03049423 daily for 90 days; Drug: PF-03049423; 3 mg of PF-03049423 daily for 90 days; Drug: PF-03049423; 6 mg of PF-03049423 daily for 90 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Any Abnormal Laboratory Test Results (Part 1* and 2)	The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.	Day 1 (Baseline) up to Day 90
Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern (Part 1* and 2)	Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (>=) 30 or 50 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (<) 90 mm Hg; diastolic BP (DBP) >=20 mm Hg change from grand baseline in same posture, diastolic <50 mm Hg; 2), pulse rate (supine, sitting and standing): <40 or greater than (>) 120 beats per minute (bpm); Standing: <40 or >140 bpm. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.	Day 1 (Baseline) up to follow-up (28 days after Day 90)
Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern (Part 1* and 2)	ECG criteria of potential clinical concern were 1), PR interval: >=300 milliseconds (msec); >=25% increase when baseline >200 msec; or increase >=50% when baseline <=200 msec; 2), QRS interval: >=140 msec; >=50% increase from baseline; 3), QT interval: >=500 msec, QTc interval using Fridericia's formula (QTcF interval): absolute value >=450 - <480 msec, >=480-<500 msec, >=500 msec; absolute change 30 - <60, >=60 msec. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.	Day 1 (Baseline) to Day 90
Number of Participants With Significant Change in Physical Examination Findings (Part 1* and 2)	The complete physical examination included examination of the skin, eyes, ears, throat, neck, cardiac, respiratory, gastrointestinal, and musculoskeletal systems. The limited physical examination included examination of the cardiac, respiratory, gastrointestinal, and musculoskeletal systems. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.	Day 1 (Baseline) up to Day 90
Number of Participants With Significant Change in Neurological Examination Findings (Part 1* and 2)	The complete neurological examination included an assessment of the motor, sensory, cranial nerves, reflexes, mental status and associated motor functions. The limited neurological exam could examine the same categories of neurologic assessments as the full examination, but would differ by the depth in the examination. The examination was required to be done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the Investigator, but had to always include an assessment of motor, vision and hearing. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.	Day 1 (Baseline) up to Day 90
Number of Participants With Suicidal Behavior and/or Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Part 1* and 2)	Data were mapped to Columbia-Classification Algorithm of Suicide Assessment (C-CASA) event codes. C-SSRS assessed if participant experienced: completed suicide (Code 1), suicide attempt (Code 2) (Response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (Code 3) ("Yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), suicidal ideation (Code 4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act/some intent to act without specific plan or with specific plan and intent), self-injurious behavior, no suicidal intent (Code 7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior"). Number of participants with "Yes" response for any of above mentioned categories was assessed. *This was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for it were not reported separately, Part 1 and 2 data were reported together.	Day 7 (Baseline) up to follow up (28 days after Day 90)
Percentage of Participants With Modified Rankin Scale (mRS) Less Than or Equal to (<=2) at Day 90 (Part 2)	The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).	Day 90

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic Hand (Part 2)	The B&B test is a measure of manual dexterity. The B&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.	Day 1 (Baseline), Day 90
Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2)	The B&B test is a measure of manual dexterity. The B&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.	Day 1 (Baseline), Day 90
Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic and Non-paretic Hands (Part 2)	The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.	Day 1 (Baseline), Day 90
Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2)	The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.	Day 1 (Baseline), Day 90
Percentage of Participants With mRS (0-1) at Day 90 (Part 2)	The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).	Day 90
Percentage of Participants With National Institutes of Health Stroke Scale (NIHSS) (0-1) at Day 90 (Part 2)	The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.	Day 90
Change From Baseline in NIHSS at Day 90 (Part 2)	The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.	Day 1 (Baseline), Day 90
Percentage of Participants With Barthel Index (BI) >= 95 and BI =100 at Day 90 (Part 2)	The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.	Day 90
BI at Day 90 (Part 2)	The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.	Day 90
Domains of Interest: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding Sub Test at Day 90 (Part 2)	The test uses a reference key, the participant had 90 seconds to pair specific numbers with given geometric figures. Responses could be written or oral. The performance measure for this task was the total number of correct responses.	Day 1 (Baseline), Day 90
Domains of Interest: Change From Baseline in RBANS Naming Sub Test at Day 90 (Part 2)	This test requires the participant to name 10 objects drawn in ink. The tester asked the participant to identify the picture. The participant had 20 seconds to respond to each picture presented. The performance measure was the number of objects named correctly.	Day 1 (Baseline), Day 90
Domains of Interest: Change From Baseline in Line Cancellation Test [(L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%)] at Day 90 (Part 2)	The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.	Day 1 (Baseline), Day 90
Domains of Interest: Change From Baseline in Line Cancellation Test at Day 90 [(L-R)/(L+R)] (Part 2)	The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.	Day 1 (Baseline), Day 90
Domains of Interest: Change From Baseline in Recognition Memory Test at Day 90 (Part 2)	This test assesses the ability to recognize pictures of objects. The participant was presented a series of pictures, a subset of which were the objects presented in the RBANS Naming Sub Test. After each picture was presented, the participant indicated either manually (ie, affirmative head nod) or verbally whether the picture was seen previously. The participant was given 5 seconds per picture to respond. The performance measure for this task was the total number of pictures correctly identified.	Day 1 (Baseline), Day 90
Gait Velocity Test at Day 90 (Part 2)	The 10-meter walk test requires a 20 meter straight path, with 5 meters for acceleration, 10 meters for steady state walking, and 5 meters for deceleration. Markers were placed at the 5 and 15 meter positions along the path. The participant began to walk "at a comfortable pace" at 1 end of the path, and continued walking until he/she reached the other end. The rater used a stopwatch to determine how much time it took for the participant to traverse the 10 meter center of the path, starting the stopwatch as soon as the participant's limb crossed the first marker and stopping the stopwatch as soon as the participant's limb crossed the second marker.	Day 90
Plasma Concentrations of PF-03049423 (Part 1 and 2)		Days 1, 2, 7, 14, 30, 60 and 90
Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Non-paretic Hand (Part 2)	The B&B test is a measure of manual dexterity. The B&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.	Day 1 (Baseline), Day 90

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause Mortality (Part 2)	Deaths regardless causality were reported.	The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product.
Mortality Directly Related to Stroke (Part 2)	Deaths caused by stroke were reported.	The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product.
Number of Participants With Neuro-worsening (Part 2)	NIHSS change of 4 points or greater.	Day 1 (Baseline) up to Day 90
Number of Participants With SBP <100 mm Hg or SBP Decline >=30 mm Hg From Immediate Pre-dose Measurement, With or Without Neuro-worsening (Defined as an NIHSS Increase of 4 Points or Greater) Within 2 Hours Post-dose (Part 2)		Day 1 (Baseline) up to Day 14
Treatment-emergent Adverse Events (AEs) Resulting in Discontinuation of Study Drug (Part 2)	An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.	Day 1 (Baseline) up to follow-up (28 days after Day 90)

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

General Publications

• Di Cesare F, Mancuso J, Woodward P, Bednar MM, Loudon PT; A9541004 Stroke Study Group. Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. J Stroke Cerebrovasc Dis. 2016 Mar;25(3):642-9. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.026. Epub 2015 Dec 28.

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start: December 1, 2010
• Primary Completion (Actual): December 1, 2013
• Study Completion (Actual): December 1, 2013

Study Registration Dates

• First Submitted: September 22, 2010
• First Submitted That Met QC Criteria: September 22, 2010
• First Posted (Estimate): September 23, 2010

Study Record Updates

• Last Update Posted (Estimate): February 19, 2016
• Last Update Submitted That Met QC Criteria: January 22, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: Phase 2 Ischemic stroke Safety and efficacy
• Additional Relevant MeSH Terms: Pathologic Processes; Necrosis; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Brain Ischemia; Infarction; Brain Infarction; Stroke; Ischemic Stroke; Ischemia; Cerebral Infarction; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Phosphodiesterase Inhibitors; Phosphodiesterase 5 Inhibitors; 3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1H)-one
• Other Study ID Numbers: A9541004; 2010-021414-32 (EudraCT Number)